-
Biotech Top Gainers – MannKind Corporation (NASDAQ:MNKD), Sangamo Biosciences, Inc. (NASDAQ:SGMO), Sequenom, Inc. (NASDAQ:SQNM), Geron Corporation (NASDAQ:GERN)
MannKind Corporation (NASDAQ:MNKD) surged 9.22%, rising again seemingly on optimism that the company is targeting a large unmet need in the ever-expanding diabetes space and its main focus is on its wonder-drug: AFREZZA. Some may be hopeful that AFREZZA is going to become the dominant player in the $44B insulin market due to its unique…
-
Biotech Stocks Under Pressures, Focus On IPOs: Sequenom, Inc. (NASDAQ:SQNM), Inovio Pharmaceuticals, AEterna Zentaris, Sarepta, InterMune, Cryolife, Biogen, Boston Scientific, Varian Medical, Warner Chilcott
In Biotech sector, IPOs, following doing nothing for years, are suddenly hot. One came roaring out of the starting gate today and several are pricing tonight. Shares of Sequenom, Inc. (NASDAQ:SQNM) plunged around 30%, a day after the life sciences firm declared a increased in its Q2 loss and encouraged analysts to cut their ratings…
-
Major Development From Biotech Stocks On News: Sarepta Therapeutics, GlaxoSmithKline, Prosensa, BioCryst, Inovio, Sequenom, Lilly, Transition Therapeutics, Illumina, Omnicare, PDL BioPharma, Questcor
Sarepta Therapeutics Inc (NASDAQ:SRPT) dropped around 19% that was the most in 14 months on investor concerns that U.S. supervisory bodies won’t consider the firm’s treatment for Duchenne muscular dystrophy on an accelerated basis. The biotechnology firm declared that it aims to seek authorization of eteplirsen in the first half of 2013 following the Food…
-
Biotechnology Stocks Swing On Major News: Gilead Sciences, HCA Holdings, Tenet Healthcare, Spectrum Pharmaceuticals, MannKind, Sequenom, ACADIA Pharmaceuticals, Dendreon, Community Health Systems
Gilead Sciences, Inc. (NASDAQ:GILD) expected to hold European Society of Cardiology Congress 2013 on Aug 31, 2013. The has the market capitalization of $87.16 billion, enterprise value of $93.52 billion. The company has the price over sales value of $8.76 whereas its price over book value of $8.58 for the most recent quarter. HCA Holdings…
-
Biotechnology Volume Gainer: Dendreon Corporation (NASDAQ:DNDN) Trading Stops
Dendreon Corporation (NASDAQ:DNDN) tumbled around 16% in previous session, as triggering a trading bring to a close, following the biotechnology firm announced lower than anticipated sales for its centerpiece cancer drug, Provenge. Dendreon’s stocks trading were stop and constraints on short sales for the stock were triggered in an attempt to maintain shares from drop…
-
The growth of biotech industry is being driven by two major factors – (VVUS, ARNA, SQNM, DNDN)
The Biotech Industry has rallied this year as the higher number of new drug approvals has raised investor confidence within the industry. The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB) and SPDR S&P Biotech (ETF) (NYSEARCA:XBI) have both risen over 25 percent so far in 2012. There was another key factor behind the Biotech Industry’s success…
-
Peregrine Pharmaceuticals (NASDAQ:PPHM) Leads Top Gainers For July In The Biotechnology Industry – (AMGN, BDSI, SRPT, SQNM, GILD, ARNA)
Shares in the biotechnology industry, which features companies such as Amgen, Inc. (NASDAQ:AMGN) and BioDelivery Sciences International, Inc. (NASDAQ:BDSI), were mixed on Monday with Peregrine Pharmaceuticals (NASDAQ:PPHM) and Sarepta Therapeutics Inc(NASDAQ:SRPT) leading gains for July. Omeros Corporation (NASDAQ:OMER) recently announced that it has discovered the proteins that activate the alternative pathway of the complement system,…
-
Five Biotechnology Stocks With Better Weekly Rating Changes – (GILD, AMGN, SQNM, ARRY, ALNY, DSCO, DUSA, GENT)
Five Biotechnology stocks have scored better grades last week, according to the Portfolio Grader list. Each of these companies has an “A” representing strong buy recommendation or “B” means overall buy recommendation. Among these stocks Array Biopharma Inc (NASDAQ:ARRY) and Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) improved to an A (“strong buy”) this week while ratings of…